Showing 5411-5420 of 10820 results for "".
- Mustela Introduces Skin-Soothing PJs for Eczema-Prone Babies and Toddlershttps://practicaldermatology.com/news/mustela-introduces-skin-soothing-pjs-for-eczema-prone-babies-and-toddlers/2459885/The Global Wellness Institute recently cited smart and healing fashion as one of the biggest trends in wellness, and the new Mustela
- TARGET PharmaSolutions Launches Real-World Study to Advance the Understanding of AD and Other IMISCshttps://practicaldermatology.com/news/target-pharmasolutions-launches-target-derm-real-world-study-to-advance-the-understanding-of-atopic-dermatitis-and-other-immune-mediated-inflammatory/2459890/TARGET PharmaSolutions, Inc., has launched its latest large-scale observational study, TARGET-DERM (NCT03661866). The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis. TARGET-DERM&
- SkinBioTherapeutics Raises Capital to Broaden Applications for Skin Biome Technologyhttps://practicaldermatology.com/news/skinbiotherapeutics-raises-capital-to-broaden-applications-for-skin-biome-technology/2459894/SkinBioTherapeutics raised close to $2M to widen potential applications for their skin biome technology, the company reports. Derived from probiotic bacteria, SkinBioTherapeutics technology is being developed for use in cosmetics, infectio
- New Guidelines Offer SRT Treatment Recommendations for Skin Cancers, Keloidshttps://practicaldermatology.com/news/new-guidelines-offer-srt-treatment-recommendations-for-skin-cancers-keloids/2459897/Superficial Radiation Therapy (SRT) should be first-line therapy for appropriate non-melanoma skin cancers in appropriate patients, according to new consensus guidelines<
- Rodan & Fields Takes on Teen Acne with Spotlesshttps://practicaldermatology.com/news/rodan-fields-takes-on-teen-acne-with-spotless/2459898/Rodan & Fields is launching Spotless, a patent-pending teen and young adult acne solution. The company is also updating its Unblemish R
- Sienna Biopharmaceuticals: Promising Topline Results for SNA-001 for Hair Removalhttps://practicaldermatology.com/news/sienna-biopharmaceuticals-promising-topline-results-for-sna-001-for-hair-removal/2459899/Topline results from the pivotal trial of Sienna Biopharmaceuticals’ SNA-001 show that the topical agent in conjunction with an 810nm diode laser was statistically superior compared to vehicle plus laser. In the study involving 65 male and female patients with white, gray, blonde, light red
- Study Shows 97% Cure Rate for Superficial Radiation Therapy for BCC and SCChttps://practicaldermatology.com/news/study-shows-97-cure-rate-for-superficial-radiation-therapy-for-bcc-and-scc/2459900/A new retrospective study shows a high cure rate exceeding 97 percent among older patients (mean age: 82.5 years) being treated for basal cell carcinoma (BCC) and squamous cell carcinomas (SCC) on their lower extremities with SRT-100TM Superficial Radiation Therapy from Sensus Hea
- Combination Surgical Excision/Laser Treatment Improves Outcomes, Patient Satisfaction for CMNhttps://practicaldermatology.com/news/combination-surgical-excisionlaser-treatment-improves-outcomes-patient-satisfaction-for-cmn/2459908/Combining lasers with surgical excision produces cosmetically superior results compared to laser-only treatments for small to medium congenital melanocytic nevi (CMN), according to a new review. The
- Encore Dermatology Shares Positive Pivotal Study Results for Impoyz for the Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/encore-dermatology-shares-positive-pivotal-study-results-for-impoyz-for-the-treatment-of-plaque-psoriasis/2459920/Impoyz Cream (clobetasol propionate) Cream, 0.025% demonstrated efficacy early with 14.2 percent of Impoyz patients achieving treatment success at day 8 versus 1.6 percent in the vehicle group, according to results of a pivitol study that were shared at the 15 th annual Maui Derm Conference. Trea
- New Data Show Cosentyx Improves Quality of Life in Patients Being Treated for Psoriasishttps://practicaldermatology.com/news/new-data-show-cosentyx-improves-quality-of-life-in-patients-being-treated-for-psoriasis/2459924/Novartis shared results from a pooled analysis of four Phase 3 clinical trials demonstrating patients with moderate to severe plaque psoriasis (PsO) treated with Cosentyx (secukinumab) 300mg reported improvements in mobility, self-care, and usual activities components of the EQ-5D-3L questionnair